Clinical Trials
Below are current clinical trials.
273 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of REGN10933+REGN10987 in hospitalized adult patients with COVID-19.
-
Rochester, Minn.
The purpose of this study is to evaluate the clinical performance of the Aptima CMV Quant assay on the Panther system in ethylenediaminetetraacetic acid (EDTA) plasma samples from solid organ transplantation recipients (SOTR) and hematopoietic stem cell transplant recipients (HSCTR).
-
Rochester, Minn.
This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B. Hospitalized subjects with influenza A or B that have either a low oxygen level or a high respiratory rate will be eligible for study participation. This study will enroll adults, children and pregnant women.
-
Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to assess the safety of PH FDC SC when administered at home by an HHNP. Patients will be assessed for safety by regular evaluation of AEs, vital signs, routine clinical laboratory tests (hematology, blood chemistry), LVEF assessments, and by physical examinations.
-
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
The purpose of this study is to understand the impact of the COVID pandemic on IBD patients, including infection rates and complications from SARS-COV2, IBD related flares, patient compliance with biologic agents, impact of lockdowns on access to IV infusion centers, need for steroid therapy and admissions for IBD related flares, and modification of medical management.
-
Rochester, Minn.
The purpose of this study is to evaluate the clinical and neurocognitive correlates of COVID-19 in patients with bipolar disorder (BD).
-
Rochester, Minn.
We are testing this hypothesis through three phases for which we have developed three protocols. In this phase, with this protocol, we have two primary aims.
- Aim 1: To assess acceptability and gather input on the design and content of an as-of-yet undistributed reminder-recall to parents of children 11-12 years of age due for an HPV dose that emphasized the pain-reducing measures and the nurse visits
- Aim 2: To evaluate the process of distributing the reminder-recalls to parents of children 11-12 years of age due for an HPV dose that emphasized the pain-reducing measures and the nurse visits
-
Scottsdale/Phoenix, Ariz.
The objective of the treatment program described here is to make benznidazole available in the United States on a compassionate-use basis for treatment of T. cruzi infection—specifically, for patients who have acute or congenital infection, reactivated infection, or chronic infection (without advanced cardiac disease)—and for prophylaxis of infection, when indicated in the setting of proven exposure. Benznidazole will be provided for individual patients who meet the eligibility criteria, on request of the treating physician, after consultation with CDC staff.
-
Rochester, Minn.
This is a multicenter prospective collection of leftover respiratory tract secretions, paired blood and NP swabs, and clinical circumstances from pediatric HCT patients, followed by next generation genomic sequencing, transcriptome analysis, protein biomarker measurement, and statistical modeling.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to gain a better understanding of the presentation, diagnostics, disease course and treatment variations, as well as the factors that may influence features of neuro-invasive Coccidioidomycosis.